We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+63.01%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$372M
AUM Growth
+$110M
Cap. Flow
+$14.9M
Cap. Flow %
4.02%
Top 10 Hldgs %
85.87%
Holding
30
New
2
Increased
12
Reduced
7
Closed
5
Avg Time Held Equity + Options
6.8 quarters
Top 10 Avg Time Held Equity + Options
3.9 quarters
Top 20 Avg Time Held Equity + Options
6.4 quarters
Avg Time Held Equity only
6.8 quarters
Top 10 Avg Time Held Equity only
3.9 quarters
Top 20 Avg Time Held Equity only
6.4 quarters

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$5.8M
2
RPTX icon
Repare Therapeutics
RPTX
+$5.45M
3
LRMR icon
Larimar Therapeutics
LRMR
+$4.76M
4
KROS icon
Keros Therapeutics
KROS
+$3.36M
5
CGEM icon
Cullinan Oncology
CGEM
+$2.63M

Top Sells

Rank Stock Value
1
GTHX icon
G1 Therapeutics, Inc. Common Stock
GTHX
+$5.06M
2
TSVT icon
2seventy bio
TSVT
+$4.3M
3
NKTX icon
Nkarta
NKTX
+$3.44M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$3.21M
5
TRDA icon
Entrada Therapeutics
TRDA
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 99.68%
2 Miscellaneous 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KZR icon
26
CALL
DELISTED
Kezar Life Sciences
KZR
– –
-10,000
Closed -$5K –
TRDA icon
27
Entrada Therapeutics
TRDA
$214M
– –
-163,496
Closed -$1.99M –
XBI icon
28
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-157,000
Closed -$372K –
EIGR
29
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-837
Closed -$4K –
PHAS
30
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-750,000
Closed -$450K –
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, CHI Advisors held 30 positions worth $372M, up 42% from $262M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

CHI Advisors deployed $14.9M of net new capital in Q3 2022, opening 2 new positions and adding to 12 existing holdings. Its largest new stake was Rallybio: 24,287 shares worth $2.81M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was G1 Therapeutics, Inc. Common Stock, an estimated $5.06M trimmed.

  • CHI Advisors's largest Q3 2022 buy was Rallybio: 24,287 shares worth $2.81M.
  • CHI Advisors added most to Pliant Therapeutics in Q3 2022, an estimated $5.8M increase.
  • CHI Advisors's biggest Q3 2022 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $5.06M.
  • CHI Advisors fully exited Entrada Therapeutics in Q3 2022, selling an estimated $1.99M.
  • CHI Advisors's ten largest holdings make up 86% of its $372M portfolio in Q3 2022.
  • CHI Advisors opened 2 new positions and closed 5 in Q3 2022.
  • CHI Advisors's portfolio value rose 42% quarter-over-quarter to $372M.

Based on CHI Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.